Attovia Therapeutics, Inc. (Ticker: ATTO US) is an American clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated diseases using its licensed ATTOBODY nanobody-based platform. Incorporated in Delaware and headquartered in San Carlos, California, the company has no approved products or product-sales revenue.

Attovia plans to list on Nasdaq on August 5, 2026. The company is offering 12.5 million shares at an expected price range of $15.00 to $17.00 per share, seeking to raise approximately $200 million at the $16.00 midpoint. Its estimated market capitalization at the offering is approximately $616 million.

The company’s lead candidate, ATTO-1310, targets IL-31 and completed dosing in a Phase 1 trial involving healthy volunteers and patients with chronic pruritus and atopic dermatitis in the first quarter of 2026. Its pipeline also includes ATTO-2306, a bispecific candidate targeting IL-13 and IL-31, and ATTO-1091, a trispecific candidate being developed for inflammatory bowel disease. Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital are managing the offering.

Vogenx, Inc. (Ticker: VOGX US) is an American biotechnology company developing medicines for hormone-related and metabolic conditions, particularly low blood sugar after bariatric surgery and gastroparesis, a condition that slows digestion. Incorporated in Delaware and based in Raleigh, North Carolina, the company has not generated revenue.

Vogenx plans to list on Nasdaq on August 6, 2026. It is offering 6.25 million shares at an expected price range of $11.00 to $13.00 per share, seeking to raise approximately $75 million. Its estimated market capitalization at the offering is approximately $167 million.

The company’s lead drug candidate, mizagliflozin, is a pill being tested in a Phase 2b study for post-bariatric hypoglycemia, which causes blood sugar to fall too low after weight-loss surgery. Vogenx licensed most worldwide rights to the drug from Kissei Pharmaceutical, excluding Japan, Korea and Taiwan. It also plans to study mizagliflozin in gastroparesis and a rare form of Cushing’s syndrome, subject to funding and regulatory approval. JonesTrading is managing the offering.

Braveheart Bio, Inc. (Ticker: BRVE US) is an American clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Incorporated in Delaware and headquartered in San Francisco, the company’s lead candidate, BHB-1893, is being evaluated for obstructive and non-obstructive hypertrophic cardiomyopathy.

Braveheart Bio plans to list on Nasdaq on August 6, 2026. The company is offering 18.8 million shares at an expected price range of $15.00 to $17.00 per share, seeking to raise approximately $300 million at the $16.00 midpoint. Its estimated market capitalization at the offering is around $1.1 billion.

BHB-1893 was discovered and initially developed by China-based Jiangsu Hengrui Pharmaceuticals, from which Braveheart Bio obtained exclusive licensing rights. The company plans to begin a global Phase 3 trial in obstructive hypertrophic cardiomyopathy in the second half of 2026 and another Phase 3 trial in non-obstructive disease in the first half of 2027. Braveheart Bio has not generated product revenue. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are managing the offering.

NASN Intelligent Tech (Zhejiang) Co., Ltd. (Ticker: 2261 HK) is a Chinese intelligent-driving motion-control technology company specializing in brake-by-wire systems, chassis electronic controls and steering components designed to improve vehicle safety, comfort and efficiency. Founded in 2016 and based in Hangzhou, China, NASN plans to list on the Hong Kong Stock Exchange on August 7, 2026.

The company is offering 57.59 million H shares at an expected price range of HK$10.42 to HK$11.18 per share, seeking to raise up to approximately HK$644 million, equivalent to approximately $82 million. The offering comprises entirely primary shares and includes a 15% greenshoe facility covering approximately 8.64 million additional shares.

NASN is backed by investors including Contemporary Amperex Technology and Hillhouse Investment. The offering is being managed by BOCI Asia, Haitong International Securities, Orient Securities Hong Kong, SDICS Securities Hong Kong and other advisers.